Natural Killer Cell

A phase 2 randomized, double-blind, placebo-controlled study of tremelimumab for second and third line treatment in patients with unresectable pleural or peritoneal mesothelioma
Lee Krug, Alessandra di Pietro, Rajesh Narwal, Paul Robbins, Dongyue Fu, Aiman Shalabi, Ramy Ibrahim, Luana Calabro, Hedy Kindler

Journal for ImmunoTherapy of Cancer Nov 2013, 1 (Suppl 1) P132; DOI: 10.1186/2051-1426-1-S1-P132
IL-18-based combinatorial adjuvants promote the NK-DC-mediated production of the CCR7 ligand CCL19 in lymph nodes from cancer patients
Jeffrey L Wong, Ravikumar Muthuswamy, David L Bartlett, Pawel Kalinski

Journal for ImmunoTherapy of Cancer Nov 2013, 1 (Suppl 1) O21; DOI: 10.1186/2051-1426-1-S1-O21
ErbB2/HER2-specific NK cells for adoptive cancer immunotherapy
Congcong Zhang, Michael Burger, Kurt Schönfeld, Sabrina Genβler, Christiane Sahm, Sonja Naundorf, Marcus Odendahl, Paulina Nowakowska, Torsten Tonn, Manuel Grez, Joachim P Steinbach, Winfried S Wels

Journal for ImmunoTherapy of Cancer Nov 2013, 1 (Suppl 1) P38; DOI: 10.1186/2051-1426-1-S1-P38
Prognostically relevant natural killer cell-mediated immunoediting in acute myeloid leukemia
Christopher J Chan, Daniel M Andrews, Mark J Smyth, Paul J Neeson, David S Ritchie

Journal for ImmunoTherapy of Cancer Nov 2013, 1 (Suppl 1) P181; DOI: 10.1186/2051-1426-1-S1-P181
Transient regulatory T-cell (Treg) depletion with IL-2 diphtheria toxin fusion protein enhances clearance of acute myeloid leukemia by haploidentical natural killer (NK) cells
Veronika Bachanova, Sarah Cooley, Todd Defor, Michael R Verneris, Bin Zhang, David McKenna, Julie Curtsinger, Angela Panoskaltsis-Mortari, Dixie Lewis, Keli Hippen, Philip McGlave, Daniel Weisdorf, Bruce R Blazar, Jeffrey S Miller

Journal for ImmunoTherapy of Cancer Nov 2013, 1 (Suppl 1) P1; DOI: 10.1186/2051-1426-1-S1-P1
Combination chemoimmunotherapy with monthly cycles of 5-fluorouracil + interferon-alfa-2b in previously-treated advanced cancer
Walter Quan, Vivek Khemka, Laura S Martell, Marci J Pierog

Journal for ImmunoTherapy of Cancer Nov 2013, 1 (Suppl 1) P85; DOI: 10.1186/2051-1426-1-S1-P85
Evaluation of aerosol IL-2 in sarcoma patients with lung metastases for future combination therapy with infused natural killer cells
Aung Naing, Pete Anderson, Sergei Guma, Hsuan-Chu Chien, Lacey MM McQuinn, Joshua P Hein, Ralph G Zinner, Eugenie S Kleinerman, Nancy Gordon

Journal for ImmunoTherapy of Cancer Nov 2013, 1 (Suppl 1) P251; DOI: 10.1186/2051-1426-1-S1-P251
Single-cell quantification of functional outcomes of CD16 ligation in NK cells by Fc-engineered antibodies
Gabrielle Romain, Vladimir V Senyukov, Ivan Liadi, William Kelton, George Georgiou, Dean A Lee, Navin Varadarajan

Journal for ImmunoTherapy of Cancer Nov 2013, 1 (Suppl 1) O5; DOI: 10.1186/2051-1426-1-S1-O5
P67. Targeted natural killer (NK) cell based adoptive immunotherapy for the treatment of patients with non-small cell lung cancer (NSCLC) after radiochemotherapy (RCT) – clinical application of NK cells activated by heat shock protein 70 (Hsp70)
HM Specht, J Pelzel, H Hautmann, RM Huber, B Schossow, M Molls, G Multhoff

Journal for ImmunoTherapy of Cancer Mar 2014, 2 (Suppl 2) P41; DOI: 10.1186/2051-1426-2-S2-P41
P24. Aviscumine enhances NK- cytotoxicity against tumor cells
G Gamerith, A Amann, B Schenk, T Auer, JM Huber, K Cima, H Lentzen, J Löffler-Ragg, H Zwierzina, W Hilbe

Journal for ImmunoTherapy of Cancer Mar 2014, 2 (Suppl 2) P15; DOI: 10.1186/2051-1426-2-S2-P15

Main menu

Natural Killer Cell

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

Natural Killer Cell

Pages